Emergent BioSolutions (NYSE:EBS) Board Announces Stock Repurchase Plan

Emergent BioSolutions (NYSE:EBS) declared that its board has approved a share repurchase plan on Monday, March 31st, RTT News reports. The company plans to buyback $50.00 million in shares. This buyback authorization permits the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $4.74 on Wednesday. The business’s 50 day moving average price is $7.83 and its 200-day moving average price is $8.61. Emergent BioSolutions has a fifty-two week low of $1.82 and a fifty-two week high of $15.10. The company has a market cap of $257.45 million, a P/E ratio of -1.16 and a beta of 1.80. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. The business had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter in the previous year, the business posted ($0.77) earnings per share. Sell-side analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.